GLAND2,950.00

Gland Pharma Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹48,604 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations5,664.75,616.56,430.76,725.3
Other Income170.2213.6316.3320.0
Total Income5,835.05,830.16,747.07,045.3
Expenses
+ Cost of Materials Consumed2,022.11,972.52,239.72,270.6
+ Purchases of Stock-in-Trade23.114.56.67.7
+ Changes in Inventories127.9103.4-3.467.9
+ Employee Benefit Expense1,256.91,401.61,628.81,664.8
+ Finance Costs26.242.033.326.1
+ Depreciation & Amortisation344.6377.9423.7433.9
+ Other Expenses901.7855.6929.3963.2
Total Expenses4,702.44,767.55,258.15,434.2
EBITDA1,333.11,268.91,629.51,751.1
EBIT988.5891.11,205.91,317.3
Profit
PBT before Exceptional Items1,132.51,062.71,488.91,611.2
+ Exceptional Items0.00.0-24.3-24.3
Pretax Income1,132.51,062.71,464.61,586.8
+ Current Tax345.7372.0458.9482.4
+ Deferred Tax14.3-7.8-21.6-24.3
Tax Expense360.1364.1437.3458.0
Net Income772.5698.51,027.31,128.8
+ Net Income — Continuing Ops772.5698.51,027.31,128.8
+ Other Comprehensive Income-7.955.4431.0217.8
Total Comprehensive Income764.6753.91,458.31,346.6
Net Income to Common772.5698.51,027.31,128.8
Per Share
Basic EPS46.9042.4062.3568.51
Diluted EPS46.8942.4062.2868.47
Other Comprehensive Income — detail
+ Other Comprehensive Income55.4431.0217.8
+ Items NOT to be Reclassified to P&L-2.5-1.613.617.4
+ Tax on Items NOT to be Reclassified-0.43.44.3
+ Tax on Items NOT to be Reclassified — alt tag-0.6
+ Items to be Reclassified to P&L420.9204.7
+ Tax on Items to be Reclassified-56.60.00.0
+ Tax on Items to be Reclassified — alt tag6.0
Comprehensive Income — Owners of Parent764.6753.91,458.31,346.6
Per Share — as-filed variants
Basic EPS — Continuing Operations46.9042.4062.3568.51
Diluted EPS — Continuing Operations46.8942.4062.2868.47
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit3,491.63,526.14,187.74,379.2
Gross Margin %61.6462.7865.1265.11
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)1,132.51,062.71,488.91,611.2
− Exceptional Items (reconciliation)0.00.0-24.3-24.3
Net Income Adj (tax-effected)772.5698.51,044.41,146.1
EPS Adj46.9042.4063.3969.56
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital16.516.516.516.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.